Comparative Pharmacology
Head-to-head clinical analysis: AJOVY versus QULIPTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AJOVY versus QULIPTA.
AJOVY vs QULIPTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ajovy (fremanezumab) is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) and blocks its binding to the CGRP receptor, thereby inhibiting CGRP-mediated neurogenic vasodilation and pain transmission in trigeminal sensory neurons.
QULIPTA (atogepant) is a calcitonin gene-related peptide (CGRP) receptor antagonist. It competitively blocks the binding of CGRP to its receptor, thereby inhibiting CGRP-mediated vasodilation and pain transmission involved in migraine pathophysiology.
AJOVY (fremanezumab-vfrm) is administered subcutaneously at a dose of 675 mg once every 3 months (quarterly) or 225 mg once monthly. The injection volume is 1.5 mL for the 225 mg dose and 4.5 mL for the 675 mg dose, administered as three separate injections of 225 mg each.
10 mg orally once daily
None Documented
None Documented
Terminal elimination half-life is 31 days (range 23-37 days). This long half-life supports monthly subcutaneous dosing.
Terminal elimination half-life is approximately 21 hours, supporting once-daily dosing.
Renal excretion of intact antibody is minimal; metabolized via catabolism to peptides and amino acids. Approximately 100% of elimination is via intracellular degradation (proteolysis) and biliary excretion of metabolites, with negligible renal excretion.
Approximately 60% of the dose is excreted in feces (as unchanged drug and metabolites) and 40% in urine (primarily as metabolites, with <1% unchanged).
Category C
Category C
CGRP Antagonist
CGRP Antagonist